Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Kirstin Thelen"'
Autor:
Tianxing Liu, Kensei Hashizume, Eva Krieg, Huijun Chen, Yuki Mukaida, Kirstin Thelen, Frauke Friedrichs, Stefan Willmann, Stephan Schwers, Alexander Solms, Rosie Yu
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 4, Pp n/a-n/a (2024)
Abstract The inhibition of coagulation factor XI (FXI) presents an attractive approach for anticoagulation as it is not expected to increase the risk of clinically relevant bleeding and is anticipated to be at least as effective as currently availabl
Externí odkaz:
https://doaj.org/article/cb479031dd4144f68d40844bb322cbcc
Autor:
Stefan Willmann, Ibrahim Ince, Maurice Ahsman, Katrin Coboeken, Yang Zhang, Kirstin Thelen, Dagmar Kubitza, Peter Zannikos, Wangda Zhou, Liza Miriam Pina, Teun Post, Jörg Lippert
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 8, Pp 1111-1121 (2022)
Abstract Rivaroxaban is approved in various regions for the treatment of acute venous thromboembolism (VTE) in children aged between 0 and 18 years and was recently investigated for thromboprophylaxis in children aged between 2 and 8 years (with body
Externí odkaz:
https://doaj.org/article/84f2ca20cce34d809d5416226dfd0fe3
Autor:
Stefan Willmann, Katrin Coboeken, Yang Zhang, Hannah Mayer, Ibrahim Ince, Emir Mesic, Kirstin Thelen, Dagmar Kubitza, Anthonie W. A. Lensing, Haitao Yang, Peijuan Zhu, Wolfgang Mück, Henk‐Jan Drenth, Jörg Lippert
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1195-1207 (2021)
Abstract Rivaroxaban has been investigated in the EINSTEIN‐Jr program for the treatment of acute venous thromboembolism (VTE) in children aged 0 to 18 years and in the UNIVERSE program for thromboprophylaxis in children aged 2 to 8 years with conge
Externí odkaz:
https://doaj.org/article/b607066a22fb4e818ec3a9900c55f325
Autor:
Dagmar Kubitza, Stefan Willmann, Michael Becka, Kirstin Thelen, Guy Young, Leonardo R. Brandão, Paul Monagle, Christoph Male, Anthony Chan, Gili Kennet, Ida Martinelli, Paola Saracco, Anthonie W. A. Lensing
Publikováno v:
Thrombosis Journal, Vol 16, Iss 1, Pp 1-13 (2018)
Abstract Background The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults. Methods This was a multinational, single-dose, o
Externí odkaz:
https://doaj.org/article/54dcb320922a486c92a064cfcc19124a
Autor:
Stefan Willmann, Kirstin Thelen, Dagmar Kubitza, Anthonie W. A. Lensing, Matthias Frede, Katrin Coboeken, Jan Stampfuss, Rolf Burghaus, Wolfgang Mück, Jörg Lippert
Publikováno v:
Thrombosis Journal, Vol 16, Iss 1, Pp 1-12 (2018)
Abstract Background The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults. A physiologically based pharmacokinetic (PBPK) m
Externí odkaz:
https://doaj.org/article/cd6a4e691d8a432894fe4658e16270e0
Autor:
Anthonie W. A. Lensing, Christoph Male, Guy Young, Dagmar Kubitza, Gili Kenet, M. Patricia Massicotte, Anthony Chan, Angelo C. Molinari, Ulrike Nowak-Goettl, Ákos F. Pap, Ivet Adalbo, William T. Smith, Amy Mason, Kirstin Thelen, Scott D. Berkowitz, Mark Crowther, Stephan Schmidt, Victoria Price, Martin H. Prins, Paul Monagle
Publikováno v:
Thrombosis Journal, Vol 16, Iss 1, Pp 1-11 (2018)
Abstract Background Venous thromboembolism (VTE) is a relatively rare condition in childhood with treatment mainly based on extrapolation from studies in adults. Therefore, clinical trials of anticoagulation in children require novel approaches to de
Externí odkaz:
https://doaj.org/article/b6a58605a3f245d0935f0be64bd90cdc
Autor:
Anthony Chan, Anthonie W. A. Lensing, Dagmar Kubitza, Grahaem Brown, Dolores Elorza, Marta Ybarra, Jacqueline Halton, Sebastian Grunt, Gili Kenet, Damien Bonnet, Amparo Santamaria, Paola Saracco, Tina Biss, Francesco Climent, Philip Connor, Joseph Palumbo, Kirstin Thelen, William T. Smith, Amy Mason, Ivet Adalbo, Scott D. Berkowitz, Eva Hurst, Jeroen van Kesteren, Guy Young, Paul Monagle
Publikováno v:
Thrombosis Journal, Vol 16, Iss 1, Pp 1-9 (2018)
Abstract Background Venous thromboembolism (VTE) in young children is not well documented. Methods Clinicians from 12 institutions retrospectively evaluated the presentation, therapeutic management, and outcome of VTE in children younger than 2 years
Externí odkaz:
https://doaj.org/article/7fec6cb3488a49e0a905b43294ad0ded
Autor:
Joseph S. Palumbo, Anthonie W. A. Lensing, Leonardo R. Brandão, Hélène L. Hooimeijer, Gili Kenet, Heleen van Ommen, Akos F. Pap, Madhurima Majumder, Dagmar Kubitza, Kirstin Thelen, Stefan Willmann, Martin H. Prins, Paul Monagle, Christoph Male
Publikováno v:
Blood advances, 6(22), 5821-5828. American Society of Hematology
Blood advances, 6(22), 5821-5828. The American Society of Hematology
Blood Advances, 6(22), 5821-5828. AMER SOC HEMATOLOGY
Blood advances, 6(22), 5821-5828. The American Society of Hematology
Blood Advances, 6(22), 5821-5828. AMER SOC HEMATOLOGY
Anticoagulant treatment of pediatric cancer–associated venous thromboembolism (VTE) has not been prospectively evaluated. Management of anticoagulation for cancer-associated VTE is often challenged by drug interactions and treatment interruptions.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2508f0ed2690a65c6cd0c9468bfa66c8
https://pure.eur.nl/en/publications/c72ae668-442d-4a7f-8998-8a42352e6016
https://pure.eur.nl/en/publications/c72ae668-442d-4a7f-8998-8a42352e6016
Autor:
Dagmar Kubitza, Yang Zhang, Wolfgang Mück, Anthonie W. A. Lensing, Henk-Jan Drenth, Emir Mesic, Stefan Willmann, Hannah Mayer, Peijuan Zhu, Haitao Yang, Katrin Coboeken, Kirstin Thelen, Jörg Lippert, Ibrahim Ince
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1195-1207 (2021)
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1195-1207 (2021)
Rivaroxaban has been investigated in the EINSTEIN‐Jr program for the treatment of acute venous thromboembolism (VTE) in children aged 0 to 18 years and in the UNIVERSE program for thromboprophylaxis in children aged 2 to 8 years with congenital hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6131886bef6963f377da23719d36fac1
https://doi.org/10.1002/psp4.12688
https://doi.org/10.1002/psp4.12688
Autor:
Stephan Schwers, Sigrun Unger, Sonja Schiffer, Ashraf Yassen, Dirk Thomas, Stefanie Kraff, Kirstin Thelen, Stefanie Boxnick
Publikováno v:
Research and Practice in Thrombosis and Haemostasis
Background Coagulation factor XI (FXI) contributes to the development of thrombosis but appears to play only a minor role in hemostasis and is therefore an attractive anticoagulant drug target. Objectives To evaluate the safety, pharmacodynamic, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e27ba5410572585228602e6a12306082
https://doi.org/10.1002/rth2.12186
https://doi.org/10.1002/rth2.12186